Introduction: Oral vaccines delivered as tablets offer a number of advantages over traditional
INTRODUCTION
Licensed vaccines today use three (two A and one B) or four (two A and two B) strains that are predicted to be circulating in the population. The additional B strain in the quadrivalent vaccine is due to the fact that there are two B lineages (B/ Yamagata and B/Victoria) currently in co-circulation and there is limited cross protection between strains from each lineage [2] . In a study using UK data, it was estimated that the inclusion of an additional B strain to generate a quadrivalent vaccine could be expected to reduce the number of influenza cases by 17,088 and deaths by 168 in the first year of use [3] . Although adding four strains may reduce the possibility of B strain mismatch, strain mismatch can still occur as was the case for the 2014/15 Northern Hemisphere influenza season, where the predominant H3N2 strain drifted [34] , with the result that the vaccine was only partially protective (vaccine effectiveness of only 23%) [35] . While four strains may be better than one, strain selection is by no means perfect.
An additional issue that arises with multivalent vaccines is the possibility of immunological interference effects between the individual vaccine components. Interference can result in a diminished or an enhanced response to one component in the presence of another. This has been documented for live attenuated influenza vaccines [4] , and where it occurs, dosing may have to be modified to counteract this interference [5] .
As new quadrivalent vaccines are developed, interference effects need to be studied for each new vaccine.
We have been developing an oral-based adenovirus platform for vaccine delivery. The vaccine platform consists of a replication-incompetent adenovirus vector bearing two expression cassettes that express a vaccine antigen and a double-stranded RNA (dsRNA) adjuvant [6] . The vaccine antigen that we have chosen for the influenza vaccine is influenza hemagglutinin (HA), an envelope glycoprotein involved in receptor binding and viral fusion. Antibodies that block the ability of HA to bind to target cells, as measured by the HA inhibition (HAI) titer, have been found to correlate with protection [7] . This oral vaccine approach has a number of advantages over traditional influenza vaccines. These include ease of manufacturing, using standard recombinant techniques and established viral purification methods; ease of delivery without needles or other devices that need qualified medical support; long-term stability at room temperature negating the need for cold storage. This oral platform also generates minimal anti-vector immunity thus permitting revaccination and reuse [6] . We have generated HA-based recombinant adenovirus (rAd) vaccine vectors to individual influenza strains and demonstrated either protection in small animals [6] or immunogenicity in humans [8, 9] 
HA Assays
Total anti-HA antibodies were measured similarly as previously described [6] . and 56) on the same plate and a titer was assigned as the reciprocal of the highest dilution of the test sample where the value was greater than the corresponding day 0 dilution by 0.04 or greater. The absorbance value also had to be greater than the average background (based on blocking buffer alone) plus two SDs.
HAI titers were measured by Focus Diagnostics (Cypress, CA, USA). The HAI protocol was followed as described before [13] using four HA units of the relevant viruses. In Microneutralization (MN) assays for both the blended B and quadrivalent ferret studies were performed by SRI following a protocol described by Rowe et al. [15] . In brief, sera were inactivated at 56°C for 30 min and twofold serial dilutions were made in 1% BSA/DMEM/ 1X penicillin/streptomycin. The diluted sera (50 lL) was mixed with an equal volume of influenza viruses at 2 9 10 3 tissue culture infectious dose 50 (TCID50)/mL and incubated for 18 h at 37°C. Control wells of virus plus dilution buffer or dilution buffer alone were included on each plate. 100 lL of MDCK cells at 1.5 9 10 5 /mL was added to each well. The plates were incubated for 18 h at 37°C and 5% CO 2 .
The monolayers were washed with PBS and fixed in cold 80% acetone for 10 min. indicating substantial cross reactivity (Fig. 3) . IU, and B virus at 2 9 10 7 IU. Sera were harvested at 3 weeks and an anti-HA IgG ELISA was performed. N = 6/group for all groups, except N = 5 for 1:10:1 blended group. Ad adenovirus, CI confidence interval, ELISA enzyme-linked immunosorbent assay, GMT geometric mean titer, HA hemagglutinin, IgG immunoglobulin, i.n. intra-nasal, p.o. peroral control for delivery, monovalent vectors were also given by i.m. injection using the same dose as p.o. As was seen in mice, both vectors elicited some cross reactivity to the homologous antigen and to the cross lineage antigen (Fig. 4) . As an example, the Wisconsin HA-treated animals generated a similar antibody response to both B/Wisconsin/1/10 and B/Brisbane/60/08 HA proteins as measured by ELISA. The Ad-B/Bris immunized animals had a substantial response to B/Brisbane/60/08 HA but the response to B/Wisconsin/1/10 HA was quite varied with some animals having a much reduced response compared to the Ad-B/ Wis vaccine. The blended B-treated animals generated a similar antibody response to both HA types with GMTs of 1.22 9 10 4 ± 3.43 9 10 4 and 1.22 9 10 4 ± 3.5 9 10 4 , respectively (Fig. 4) .
RESULTS

Monovalent and Blended Vectors
In addition to total antibody titers, HAI and MN assays were performed to detect antibodies that could either prevent hemagglutination (Fig. 4b) or those that could neutralize influenza viruses (Fig. 4c) . HAI assays were performed for all groups to both Brisbane and Total anti-HA antibody at 8 weeks is presented in Fig. 5a . The percent responders are shown in Table 1 . Nearly all animals in all groups HAI analysis was performed for all groups.
The HAI titers were not significantly different between quadrivalent and monovalent vaccine groups (P = 0.22-0.96) with the exception of the H3 monovalent versus the quadrivalent which indicated that the monovalent induced a higher H3 HAI response ( Fig. 5b ; P = 0.02 by Mann-Whitney analysis).
MN data trended similar to HAI titers though the percent responders and the absolute geometric titers were in general lower (Fig. 5c ) for all groups including the TIV group which elicited no MN titers greater than 29 the assay background of 10.
Only 20% of the quadrivalent group responded (49 above background) to H1N1 and B/Wisconsin/ 1/10 ( Table 2 ). This increased to 40% responders for B/Wisconsin/1/10 if a 29 above background criteria was used. There were no MN titers detected to B/Brisbane/60/08, which is consistent with our experience in that this HA appears to be less immunogenic than other HAs tested.
A direct head to head comparison between TIV and the oral quadrivalent (Oral Quad) vaccine for HAI is shown in Fig. 5d . TIV was given as a full human dose (45 lg) protein. GMT HAI at 8 weeks was higher for the H3 and H1 components compared to TIV. The TIV failed to elicit anti-H1 or H3 HAI responses despite the fact that these animals had generated a relatively strong total HA antibody response as measured by ELISA. The proportion of 29 HAI responders was significantly better with the oral Quad than TIV for H1 HAI and trended higher for H3 HAI (P = 0.001, P = 0.07 by Fisher's exact test), and trended higher for 49 HAI responses (P = 0.07, P = 0.23 by Fisher's exact test). Table 3 has detailed these comparisons. The Ad-B/ Bris monovalent (GMT 16.25 ± 73.98) and the quadrivalent vaccine (11.23 ± 10.59) had about the same anti-B HAI response as TIV (16.82 ± 14.14; Fig. 5b, d ). TIV had a similar number of B/Brisbane/60/08 responders compared to the quad vector, 50 versus 40% for 49 above background (background is 5), 100 versus 40% for 29 above background ( Table 2) .
As there is no B/Yamagata component in TIV, the anti-Wisconsin/1/10 HAI response cannot be compared. Ad-Perth/Ad-CA409 ND ND 100 100
Ad particles [17] , or the use of bacterial expressed flagellin-HA chimeras as injectable vaccines [18] . Similarly, our approach is a departure from traditional egg-derived influenza vaccines, using cell culture-derived adenovirus as a vector. Instead of injecting a subunit of HA, our approach delivers a vector that co-expresses influenza HA and a dsRNA adjuvant to improve immune recognition of the HA [6] . We have delivered vaccine to humans in tablet or in liquid form, with the tablet showing slightly better HAI responses (Liebowitz et al. [8] and Kim et al., unpublished data). The current study demonstrates that this platform can be used to generate multivalent adenovirus vaccines, and is achieved by blending multiple monovalent vaccine vectors. This study is unique as it is the first published study using adenoviruses as vaccine vectors for a quadrivalent influenza vaccine and using an oral model of delivery. responses as we previously demonstrated that protection against H5N1 using this platform correlated with total antibody and not HAI [6] .
The rAd doses tested in ferrets in this study were relatively low (1-10%) compared to human doses where we have seen substantial immune responses in clinical trials [8, 9] and compare well with the immune response generated to a full human dose of TIV that we evaluated concurrently. The HA protein made from a gene-based vaccine, such as ours, cannot be measured because it is made inside each subject or animal, so the best way to compare is in equivalent human doses.
Of interest was the fact that the TIV vaccine at a full human dose, by the recommended route of delivery, only induced HAI responses to B/Brisbane, and no HAI responses to A/H1N1 or A/H3N2. A published study by Skowronski et al. [19] has also noted that TIV vaccines are poor HAI inducers in influenza-naive ferrets. Pearce et al. [20] found in ferrets that the best HAI [6, 31] . In our human tablet study, pre-existing immunity to adenovirus 5 had no effect on the ability to elicit HAI responses; the subject with the highest HAI response to the vaccine also had the highest pre-existing anti-adenovirus neutralizing antibody response [8] .
Future human trials will likely follow a similar path as our ferret studies, first testing A and B monovalent vaccines and then testing combinations to evaluate efficacy and possible interference effects. Multivalent approaches using either DNA or viral vectors such as Ad are not new. A DNA vaccination approach in mice using blends of HA expressing plasmids against multiple H3 strains increased the breath of protection to multiple strains compared to monovalent vaccines alone [32] . Blends of adenovirus vaccine vectors expressing HIV antigens have previously been tested in animals without signs of immunological interference between vaccine antigens [33] .
Given our success of this oral platform in humans, plus the encouraging response described here in ferrets, it is our intention to evaluate such blends in future human trials.
Only through clinical trials can it be determined whether such multivalent vaccines will prove efficacious as vaccines. 
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